Ovid Therapeutics Inc. (OVID)

USD 0.29

(0.77%)

Market Cap (In USD)

20.44 Million

Revenue (In USD)

391.69 Thousand

Net Income (In USD)

-52.33 Million

Avg. Volume

400.78 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.68-4.1
PE
-0.78
EPS
-0.37
Beta Value
0.41
ISIN
US6904691010
CUSIP
690469101
CIK
1636651
Shares
71075005.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Employee Count
-
Website
https://www.ovidrx.com
Ipo Date
2017-05-05
Details
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.